http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 홍철호 ( Cheul Ho Hong ) (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
홍철호 ( Cheul Ho Hong ),박동일 ( Dong Il Park ),최우혁 ( Woo Hyuk Choi ),박정호 ( Jung Ho Park ),김홍주 ( Hong Joo Kim ),조용균 ( Yong Kyun Cho ),손정일 ( Chong Il Sohn ),전우규 ( Woo Kyu Jeon ),김병익 ( Byung Ik Kim ),김동훈 ( D 대한소화기학회 2009 대한소화기학회지 Vol.53 No.1
목적: 국한 위염은 크론병의 진단에 있어 특이 표지자로 제시되어 왔다. 그러나, 크론병과 궤양성 대장염을 구별하는 데 있어 국한 위염의 임상 유용성은 아직 불확실하며, 한국인 염증성 장질환 환자들에서 국한 위염의 발생빈도는 알려져 있지 않다. 이번 연구에서는 한국인 크론병과 궤양성 대장염 환자들에서 국한 위염의 빈도와 그 외의 위 조직소견에 대해 조사하였다. 대상 및 방법: 이번 연구는 37명의 크론병 환자와 43명의 궤양성 대장염 환자, 그리고 41명의 염증성 장질환이 없는 대조군을 대상으로 하였다. 대상 환자 모두 상부위장관 내시경 및 위체부와 전정부에서 조직검사를 시행받았고 H. pylori 감염 유무도 조사하였다. 국한 위염은 최소 한 개의 상피와(foveola) 또는 몇 개의 상피와와 위선(gastric glands)을 둘러싸는 잘 경계 지워지는 조직구, 림프구, 과립구들로 구성된 염증세포들의 침윤이 있는 경우로 정의하였다. 결과: 크론병 환자에서 H. pylori 양성률은 27% (10/37), 궤양성 대장염 환자에서는 37.2% (16/43)였고, 대조군에서는 53.7% (22/41)였다(p=0.054). H. pylori 음성인 환자들을 대상으로 하였을 때 국한 위염의 양성률은 크론병 환자, 궤양성 대장염 환자 및 대조군에서 각각 29.6% (8/27), 22.2% (6/27) 및 10.5% (2/9)였다(p=0.324). 결론: H. pylori 음성인 환자들에서 국한 위염은 크론병뿐만 아니라 궤양성 대장염 환자 및 대조군에서도 관찰되며, 크론병에 진단적이지 못했다. Background/Aims: Focally enhanced gastritis (FEG) has been suggested as a specific diagnostic marker for patients with Crohn`s disease (CD). However, the usefulness of FEG for distinguishing CD from ulcerative colitis (UC) is uncertain and the incidence or prevalence of FEG for inflammatory bowel disease (IBD) patients in Korea has not been defined yet. In this study, we investigated the frequency of FEG and other gastric histological abnormalities in Korean patients with CD and UC. Methods: We evaluated 37 patients with known CD, 43 patients with UC and 41 non-IBD control group; all underwent upper gastrointestinal endoscopy followed by biopsy from the antrum and the body. The pathology of the gastric biopsy specimens and the presence of Helicobacter pylori (H. pylori) were evaluated. FEG was characterized by a focal perifoveolar or periglandular inflammatory cell infiltrates. Results: H. pylori positive gastritis was found in 10 of 37 (27.0%) of CD patients, in 16 of 43 (37.2%) of UC patients, and in 22 of 41 (53.7%) of non-IBD control group (p=0.054). In H. pylori- negative patients, FEG was found in 8 of 27 patients (29.6%) of CD patients, 6 of 27 (22.2%) patients with UC, and 2 of 9 (10.5%) of non-IBD control group (p=0.324). Conclusions: In H. pylori-negative patients, there was no statistically significant difference in the occurrence of FEG among CD, UC and control groups in Korea. (Korean J Gastroenterol 2009;53:23-28)
-
프로톤 펌프 억제제 종류에 따른 비궤양성 소화불량증 환자와 소화성 궤양 환자의 Helicobacter pylori 제균율 비교
홍은정 ( Eun Jung Hong ),박동일 ( Dong Il Park ),오석중 ( Suk Joong Oh ),송민준 ( Min Jun Song ),최우혁 ( Woo Hyuk Choi ),홍철호 ( Cheul Ho Hong ),박정호 ( Jung Ho Park ),김홍주 ( Hong Joo Kim ),조용균 ( Yong Kyun Cho ),손정일 ( C 대한소화기학회 2008 대한소화기학회지 Vol.52 No.2
Background/Aims: Conflicting results have been reported whether patients with non-ulcer dyspepsia (NUD) respond differently to Helicobacter pylori (H. pylori) eradication treatment compared with patients with peptic ulcer diseases (PUD). The aim of this study was to evaluate any difference in H. pylori eradication rates between patients with NUD and PUD according to each proton pump inhibitor (PPI). Methods: From September, 2004 to April, 2007, we retrospectively reviewed 2,297 patients with NUD (1,050 patients) or PUD (1,247 patients) infected with H. pylori. All patients received a standard 1 week triple therapy comprising of one of the five PPIs (pantoprazole, esomeprazole, omeprazole, lansoprazole, rabeprazole), clarithromycin and amoxicillin. The follow-up H. pylori test was performed 4 weeks after the completion of therapy. Results: There was no significant difference in the eradication rates between the two groups. In comparison of eradication rates according to PPI, omeprazolebased triple therapy group showed higher eradication rate than other groups in patients with NUD, but not in patients with PUD. Conclusions: This study failed to show any difference in H. pylori eradication rate between patients with NUD and PUD. There is no convincing evidence that the eradication rate may be affected by different PPI. (Korean J Gastroenterol 2008;52:80-85)
-
Helicobacter pylori 감염 환자에서 10일 연속 제균치료의 효과
최우혁 ( Woo Hyuk Choi ),박동일 ( Dong Il Park ),오석중 ( Suk Joong Oh ),백유흠 ( Yoo Hum Baek ),홍철호 ( Cheul Ho Hong ),홍은정 ( Eun Jung Hong ),송민준 ( Min Jun Song ),박성근 ( Sung Keun Park ),박정호 ( Jung Ho Park ),김홍주 ( 대한소화기학회 2008 대한소화기학회지 Vol.51 No.5
Background/Aims: Antibiotic resistance and poor compliance are the main causes of Helicobacter pylori (H. pylori) eradication failure. Proton pump inhibitor (PPI)-based triple therapy is the most preferred regimen in clinical practice. However, a critical fall in the H. pylori eradication rate has been observed in the recent years. A novel 10 day-sequential therapy consists of five days of dual therapy followed by five days of triple therapy regimen has recently been described. We aimed to evaluate whether 10 day-sequential therapy eradicated H. pylori infection better than the PPI-based triple therapy in Korea. Methods: 158 patients with proven H. pylori infection were randomized to receive either 10 day-sequential therapy (20 mg of omeprazole, 1.0 g of amoxicillin, each administered twice daily for the first 5 days, followed by 20 mg of omeprazole, 500 mg of clarithromycin, 500 mg of metronidazole, each administered twice daily for the remaining 5 days) or PPI-based triple therapy (20 mg of omeprazole, 1.0 g of amoxicillin, 500 mg of clarithromycin, each administered twice daily for 1 week). Outcome of eradication therapy was assessed 8 weeks after the cessation of treatment. Results: Eradication rates of 10 day-sequential therapy and PPI-based triple therapy were 77.9% (60/77) and 71.6% (58/81) by intention to treat analysis, respectively (p=0.361). By per protocol analysis, eradication rates of 10 day-sequential therapy and triple therapy were 85.7% (60/70) and 76.6% (58/76), respectively (p=0.150). There were no significant differences in adverse event rates and treatment compliance between two groups. Conclusions: The 10 day-sequential therapy regimen failed to achieve significantly higher eradication rates than PPI-based triple therapy. (Korean J Gastroenterol 2008;51:280-284)
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
